Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

http://mc.manuscriptcentral.com/childneurology

Click here to sign up for SAGE Journal Email Alerts today!
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shuayto, M. I.
Right arrow Articles by Greiner, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shuayto, M. I.
Right arrow Articles by Greiner, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Administration of Intravenous Tissue Plasminogen Activator in a Pediatric Patient With Acute Ischemic Stroke

Marwan I. Shuayto, MD

Department of Neurology University of South Alabama College of Medicine, M_Shuayto_MD@yahoo. com.

J. Ivan Lopez, MD

Department of Neurology University of South Alabama College of Medicine

Frank Greiner, MD

Department of Radiology University of South Alabama College of Medicine Mobile, Alabama

Intravenous tissue plasminogen activator is the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of acute ischemic strokes. The National Institutes of Health (NIH)—sponsored study that led to the approval of tissue plasminogen activator to be used in acute ischemic strokes included only individuals 18 years of age and older. We report a case of a pediatric patient who suffered a dominant-hemisphere acute ischemic stroke who was treated with intravenous tissue plasminogen activator. Our patient's symptoms began to resolve 4 hours after treatment, and he had a complete recovery after 8 hours. The clinical outcome was excellent and without complications. Tissue plasminogen activator administration can be safe and effective in younger patients. Randomized, controlled, double-blind studies are needed. (J Child Neurol 2006;21:604— 606; DOI 10.2310/7010.2006.00142).

Journal of Child Neurology, Vol. 21, No. 7, 604-606 (2006)
DOI: 10.1177/08830738060210070701
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 StrokeHome page
M. Arnold, M. Steinlin, A. Baumann, K. Nedeltchev, L. Remonda, S. J. Moser, M.-L. Mono, G. Schroth, H. P. Mattle, and R. W. Baumgartner
Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
Stroke, March 1, 2009; 40(3): 801 - 807.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, P. C. Vroomen, and G. J. Luijckx
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke, September 1, 2007; 38(9): 2612 - 2618.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
R. Belvis
Thrombolysis for Acute Stroke in Pediatrics
Stroke, June 1, 2007; 38(6): 1722 - 1723.
[Full Text] [PDF]